Widely used:Recently Viewed
Clear All
$71 Mln
3.85
0.88
--
0
18.63 %
--
--
--
340007
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
| -12.24 | -5.84 | -1.15 | 8.40 | -58.11 | -33.97 | -- |
|
BSE Sensex*
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
| -15.03 | -89.19 | -17.43 | 101.66 | 56.34 | -47.47 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$70.80 Mln
$107.52 Mln
$0.00 Mln
$63.53 Mln
$4.94 Mln
High
$0.99 - 1.89
54,049,100
NASDAQ: SPRO
Cambridge, MA
https://sperotherapeutics.com
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's... product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 Read more
The total asset value of Spero Therapeutics Inc (SPRO) stood at $ 196 Mln as on 30-Jun-24
The share price of Spero Therapeutics Inc (SPRO) is $1.29 (NASDAQ) as of 03-Oct-2024 16:00 EDT. Spero Therapeutics Inc (SPRO) has given a return of -58.11% in the last 3 years.
Spero Therapeutics Inc (SPRO) has a market capitalisation of $ 71 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Spero Therapeutics Inc (SPRO) is 0.88 times as on 02-Oct-2024, a 72% discount to its peers’ median range of 3.12 times.
The P/E ratio of Spero Therapeutics Inc (SPRO) is 3.85 times as on 02-Oct-2024.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Spero Therapeutics Inc (SPRO) and enter the required number of quantities and click on buy to purchase the shares of Spero Therapeutics Inc (SPRO).
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139
The CEO & director of Dr. Ankit Mahadevia M.D., MBA. is Spero Therapeutics Inc (SPRO), and CFO & Sr. VP is Dr. Ankit Mahadevia M.D., MBA.
There is no promoter pledging in Spero Therapeutics Inc (SPRO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
996
|
|
|
994
|
|
|
980
|
|
|
819
|
| Spero Therapeutics Inc. (SPRO) | Ratios |
|---|---|
|
Return on equity(%)
|
18.63
|
|
Operating margin(%)
|
4.11
|
|
Net Margin(%)
|
16.23
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Spero Therapeutics Inc (SPRO) was $0 Mln.
$-0.02
